ໜ້າທຳອິດSGIOY • OTCMKTS
add
Shionogi 2 ADR Representing 1 Ord Shs
ປິດກ່ອນໜ້າ
$6,93
ຂອບເຂດລາຄາໃນມື້
$6,94 - $7,03
ຂອບເຂດລາຄາໃນປີ
$6,22 - $9,11
ມູນຄ່າຮຸ້ນຕາມລາຄາຕະຫຼາດ
1,87 ລ້ານລ້ານ JPY
ປະລິມານສະເລ່ຍ
233,49 ພັນ
ໃນຂ່າວ
ການເງິນ
ໃບລາຍງານຜົນໄດ້ຮັບ
ລາຍໄດ້
ລາຍໄດ້ສຸດທິ
(JPY) | ກ.ຍ. 2024info | ການປ່ຽນແປງ ປ/ປ |
---|---|---|
ລາຍໄດ້ | 116,38 ຕື້ | -4,00% |
ຄ່າໃຊ້ຈ່າຍການດຳເນີນການ | 52,93 ຕື້ | -3,66% |
ລາຍໄດ້ສຸດທິ | 52,50 ຕື້ | 9,30% |
ສ່ວນແບ່ງກຳໄລສຸດທິ | 45,11 | 13,86% |
ລາຍໄດ້ຕໍ່ຮຸ້ນ | — | — |
EBITDA | 53,13 ຕື້ | -5,14% |
ອັດຕາອາກອນທີ່ມີຜົນ | 8,28% | — |
ໃບດຸ່ນດ່ຽງ
ຊັບສິນທັງໝົດ
ໜີ້ສິນທັງໝົດ
(JPY) | ກ.ຍ. 2024info | ການປ່ຽນແປງ ປ/ປ |
---|---|---|
ເງິນສົດ ແລະ ລົງທຶນໄລຍະສັ້ນ | 303,40 ຕື້ | 20,22% |
ຊັບສິນທັງໝົດ | 1,46 ລ້ານລ້ານ | 3,34% |
ໜີ້ສິນທັງໝົດ | 145,93 ຕື້ | -18,09% |
ຫຸ້ນທຶນທັງໝົດ | 1,31 ລ້ານລ້ານ | — |
ຮຸ້ນທີ່ຄ້າງຈ່າຍ | 850,69 ລ້ານ | — |
ລາຄາຕໍ່ມູນຄ່າທາງບັນຊີ | 0,00 | — |
ລາຍຮັບຈາກຊັບສິນ | 8,22% | — |
ລາຍຮັບຈາກທຶນ | 9,10% | — |
ກະແສເງິນສົດ
ການປ່ຽນແປງສຸດທິເປັນເງິນສົດ
(JPY) | ກ.ຍ. 2024info | ການປ່ຽນແປງ ປ/ປ |
---|---|---|
ລາຍໄດ້ສຸດທິ | 52,50 ຕື້ | 9,30% |
ເງິນສົດຈາກການດໍາເນີນງານ | 45,30 ຕື້ | 220,14% |
ເງິນສົດຈາກການລົງທຶນ | -17,63 ຕື້ | 47,30% |
ເງິນສົດຈາກການເງິນ | -1,11 ຕື້ | 94,50% |
ການປ່ຽນແປງສຸດທິເປັນເງິນສົດ | 21,45 ຕື້ | 158,43% |
ການເງິນສະພາບຄ່ອງ | 8,02 ຕື້ | 135,46% |
ກ່ຽວກັບ
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana.
Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines.
In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan.
Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV.
The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index.
In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m. Wikipedia
ສ້າງຕັ້ງ
1878
ສໍານັກງານໃຫຍ່
ເວັບໄຊ
ພະນັກງານ
4.959